A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

April 24, 2026

Study Completion Date

July 24, 2026

Conditions
Advanced Malignant Solid Tumor
Interventions
DRUG

AK132

IV infusion, specified dose on specified days.

Trial Locations (7)

350000

Fujian Provincial Cancer Hospital, Fuzhou

410000

Hunan Provincial Cancer Hospital, Changsha

430000

Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, Wuhan

441100

Xiangyang Central Hospital, Xiangyang

510060

Sun Yat-Sen University Cancer Center, Guangzhou, China, Guangzhou

510080

Southern Medical University Nanfang Hospital, Guangzhou

510220

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akeso

INDUSTRY